MedTrace Logo

Methylation of cfDNA in Diagnosing and Monitoring Pulmonary Nodule

NCT03989219 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 401

Last updated 2022-08-08

No results posted yet for this study

Summary

Patients found pulmonary nodules by CT screening by will be enrolled in this study prospectively. Plasma cfDNA sequencing of these patients will be used to diagnose and monitor benign and malignant pulmonary nodules.

Conditions

  • Pulmonary Nodule, Solitary

Interventions

PROCEDURE

plasma cfDNA methylation

plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.

Sponsors & Collaborators

  • Jiayuan Sun

    lead OTHER

Principal Investigators

  • Jiayuan Sun, PhD · Shanghai Chest Hospital

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-15
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03989219 on ClinicalTrials.gov